CRISM Therapeutics Corporation (LSE:CRTX) reported positive preclinical results for its Docetaxel-ChemoSeed implantable delivery system, with the largest effect showing a 58% reduction in tumour volume compared with standard systemic docetaxel.
The study compared untreated control, placebo, systemic docetaxel (standard of care) and multiple Docetaxel-ChemoSeed dose levels. Docetaxel-ChemoSeed produced consistent anti-tumour activity, a dose-dependent trend supporting controlled delivery, and tumour volume reductions across several dose groups.
Tolerability favoured the ChemoSeed approach. No adverse tolerability effects or early terminations were observed in any ChemoSeed-treated groups and body weight remained stable, while systemic docetaxel was associated with reduced tolerability and multiple terminations.
"The data clearly demonstrates that delivering chemotherapy locally and continuously, rather than intermittently and systemically, provides a much-needed improvement in therapeutic efficacy and tolerability," Chris McConville, Chief Scientific Officer of CRISM Therapeutics, said:
CRISM said the results validate its strategy of localised chemotherapy and support further development of Docetaxel-ChemoSeed. The company’s most advanced programme, Irinotecan-ChemoSeed for glioblastoma, remains on track for first patients to be dosed in an open-label Phase 2 clinical trial in H1 2026.
